Copyright
©The Author(s) 2017.
World J Gastroenterol. Nov 28, 2017; 23(44): 7899-7905
Published online Nov 28, 2017. doi: 10.3748/wjg.v23.i44.7899
Published online Nov 28, 2017. doi: 10.3748/wjg.v23.i44.7899
Table 4 Association of baseline characteristics of the patients with sustained virological response treated with sofosbuvir+ribavirin (First group) n (%)
| Time point | Viral load (n = 847) | ETR (n = 847), overall ETR =100% | SVR (n = 840), overall SVR = 99.17% | Relapse (n = 7), overall relapse rate = 0.83% |
| Baseline (d-0) | ≤ 2 MIU/mL (n = 630) | 630 (100) | 628 (99.68) | 2 (0.32) |
| > 2 MIU/mL (n = 217) | 217 (100) | 212 (97.70) | 5 (2.30) | |
| RVR (weeks-4) | Negative (n = 290) | 290 (100) | 290 (100) | 0 (0) |
| ≥ 2 log drop (n = 540) | 540 (100) | 539 (99.81) | 1 (0.19) | |
| < 2 log drop (n = 17) | 17 (100) | 11 (64.70) | 6 (35.30) |
- Citation: Iqbal S, Yousuf MH, Yousaf MI. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study. World J Gastroenterol 2017; 23(44): 7899-7905
- URL: https://www.wjgnet.com/1007-9327/full/v23/i44/7899.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i44.7899